A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Treeline Biosciences, Inc.
Bayer
Shanghai Henlius Biotech
Pfizer
Eli Lilly and Company
Pfizer
Boehringer Ingelheim
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Fate Therapeutics
Alterome Therapeutics, Inc.
Hoffmann-La Roche
Pfizer
Erasca, Inc.
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
AstraZeneca
Incyte Corporation
Pfizer
Quanta Therapeutics
R-Pharm
Chugai Pharmaceutical
Tizona Therapeutics, Inc
Genentech, Inc.
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
Boehringer Ingelheim
Chugai Pharmaceutical
Quanta Therapeutics
PAQ Therapeutics, Inc.
Incyte Corporation
GlaxoSmithKline
Bristol-Myers Squibb
Fate Therapeutics
C4 Therapeutics, Inc.
Genentech, Inc.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Quanta Therapeutics
Kumquat Biosciences Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Pfizer
Celgene
Ono Pharmaceutical Co., Ltd.
Biond Biologics
Hansoh BioMedical R&D Company
Fate Therapeutics
Hanmi Pharmaceutical Company Limited
Hoffmann-La Roche